Previous Study: TRIO 022
Next Study: TRIO 020

Studies & Results

TRIO 021

A Randomized, multicenter, open-label, two-arm, Phase III neo-adjuvant study evaluating trastuzumab emtansine plus pertuzumab compared with chemotherapy plus trastuzumab emtansine and pertuzumab for patients with HER2-positive breast cancer

View FDA Study View EU Study

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org